Advertisement

Advertisement
Hematologic Malignancies
COVID-19

Patients With Hematologic Malignancies: How Robust Is Their Immunity to SARS–CoV-2?

A large study from the United Kingdom has taken a deep dive into SARS–CoV-2 in the setting of cancer, yielding both concerning and encouraging...

 

 

 

 

 

Lung Cancer
Issues in Oncology

Survey Shows Disparities in Biomarker Testing Among Underserved Patients With Lung Cancer

Recent advances in cancer genomics and targeted therapies have changed the treatment landscape for lung cancer, but disparities...

 

 

 

 

Sarcoma

Activity of Nab-sirolimus in Malignant Perivascular Epithelioid Cell Tumors

In the phase II AMPECT trial reported in the Journal of Clinical Oncology, Wagner et al found that the mTOR inhibitor nab-sirolimus...

 


Advertisement
Breast Cancer

Development of a Breast Cancer Risk Prediction Model for Black Women in the United States

As reported in the Journal of Clinical OncologyJulie R. Palmer, ScD, and colleagues have developed and validated a risk prediction...

 

 

 

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement



Sponsored Content


Issues in Oncology

Jeanne Tie, MD, MBChB, on Circulating Tumor DNA, Minimal Residual Disease, and Adjuvant Treatment

COVID-19
Global Cancer Care

Effect of the COVID-19 Pandemic on Delivery of Oncology Services in India

In a study reported in The Lancet Oncology, Ranganathan et al quantified the enormous impact of the COVID-19 pandemic on delivery of cancer services in India. Study Details The study involved data from 41 cancer centers across the nation. The delivery of oncology services between March 1 and May...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Skin Cancer

Jessica C. Hassel, MD, on Uveal Melanoma: Comparing Tebentafusp With Standard Therapies

Solid Tumors
Genomics/Genetics
Immunotherapy

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....

Solid Tumors
Genomics/Genetics
Immunotherapy

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Lung Cancer

Vamsidhar Velcheti, MD, on NSCLC: Sotorasib in KRAS-Mutated Disease

Gastroesophageal Cancer

PET Response–Adapted Chemoradiotherapy for Esophageal and Esophagogastric Junction Adenocarcinoma

As reported in the Journal of Clinical Oncology by Karyn A. Goodman, MD, and colleagues, mature results of the phase II CALGB 80803/Alliance trial indicated that treatment guided by early positron-emission tomography (PET) assessment of response to induction neoadjuvant chemotherapy improved...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...